findmyKOL
Clinical trialNCT07355205RecruitingPhase 1/PHASE2Interventional

First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

SponsorWashington University School of MedicineEnrollment26Non-small Cell Lung Cancer RecurrentNon-small Cell Lung Cancer Stage IV
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a single center, phase Ib/II study combining an anti-PD-1 antibody and an anti-CTLA-4 antibody with IL-15. It is testing the hypothesis that the addition of nogapendekin alfa inbakicept to nivolumab and ipilimumab will augment the clinical activity of those two drugs.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Giordano Fabricio Cittolin Santos, MD, PhD

    Washington University School of Medicine

    Principal Investigator
    clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Washington University School of Medicine

    St Louis, Missouri, United States

    Anjali Rohatgi, MDBrett Herzog, MD, PhDDaniel Morgensztern, MDDanielle Turlington, PharmD, BCOPGiordano Fabricio Cittolin Santos, MD, PhDJeffrey Ward, MD, PhDMaria Q Baggstrom, MDNingying Wu, PhDSaiama N Waqar, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ipilimumab →Nivolumab →Nogapendekin alfa inbakicept →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
7 Jul 2026
Primary completion
31 Jul 2032
Completion
31 Jul 2032
Last update posted
10 Jul 2026
Registered enrollment
26
Registry id
NCT07355205
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.